Selank

Overview

Selank represents the best-developed anxiolytic peptide from the Russian pharmacological tradition. Unlike benzodiazepines, it produces anxiolytic effects without sedation, tolerance development, or withdrawal — properties that have driven significant research interest and, in Russia and Ukraine, clinical registration.

GABA Modulation Without Sedation

The key clinical differentiation is the ability to reduce anxiety through GABA pathway modulation while preserving or enhancing cognitive function. This stands in direct contrast to benzodiazepines, which consistently impair memory and attention. The mechanism by which selank achieves this selectivity is not fully elucidated.

Western Research Gap

Despite a substantial Russian evidence base, there are virtually no independently conducted Western clinical trials for selank. This is the primary barrier to broader acceptance — not necessarily the evidence itself, but the concentration of that evidence within a single national research tradition.

Intranasal vs. Injectable

Intranasal delivery is commonly used due to its convenience and reasonable CNS bioavailability. Subcutaneous injection produces more consistent pharmacokinetics. Oral bioavailability is negligible due to peptide degradation in the GI tract.